Search clinical trials for: A4250 (odevixibat)

Total 16 results

Albireo

Approved for marketing

Odevixibat for the Treatment of Progressive Familial Intrahepatic Cholestasis

Progressive Familial Intrahepatic Cholestasis

United States
Albireo

Active, not recruiting

Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome (ASSERT-EXT)

Alagille Syndrome

United Kingdom, United States, France, Germany, Netherlands, Italy, Belgium, Malaysia, Poland, Turkey
Albireo

Active, not recruiting

Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFIC

Progressive Familial Intrahepatic Cholestasis

United States, Spain, Netherlands, United Kingdom, Turkey, Canada, Italy, Germany, France, Israel, Australia, Belgium, Poland, Saudi Arabia, Sweden
Albireo

Completed

Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome (ASSERT)

Alagille Syndrome

United States, United Kingdom, France, Germany, Canada, Netherlands, Italy, Malaysia, Belgium, Israel, New Zealand, Poland, Turkey
Albireo

Completed

This Study Will Investigate the Efficacy and Safety of A4250 in Children With PFIC Types 1 or 2 (PEDFIC 1)

PFIC1 | PFIC2

United States, Spain, Netherlands, United Kingdom, Turkey, Canada, Belgium, Italy, Germany, Saudi Arabia, France, Israel, Australia, Sweden, Poland
Albireo

Enrolling by invitation

An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia (BOLD-EXT)

Biliary Atresia

Spain, United States, Netherlands, Malaysia, Canada, Germany, Turkey, Italy, France, Australia, Poland, New Zealand
Albireo

Completed

A4250, an IBAT Inhibitor in Pediatric Cholestasis

Pediatric Cholestasis

United Kingdom, Denmark, France, Germany, Sweden
Sahlgrenska University Hospital, Sweden
Albireo

Terminated

IBAT Inhibitor A4250 for Cholestatic Pruritus

Biliary Cirrhosis, Primary

Sweden
Albireo
Celerion

Completed

Study of A4250 in Healthy Volunteers Under Fasting, Fed and Sprinkled Conditions

Healthy Volunteers

United States
Albireo

Recruiting

Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)

Biliary Atresia

Netherlands, United States, Spain, Italy, Taiwan, Korea, Republic of, France, Germany, United Kingdom, Canada, Belgium, China, Australia, Poland, Turkey, Malaysia, New Zealand, Hungary, Israel
Albireo

Completed

An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects

Primary Biliary Cirrhosis | Alagille Syndrome | Progressive Familial Intrahepatic Cholestasis | Orphan Cholestatic Liver Diseases

United Kingdom
Shanghai Ark Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study to Evaluate the Efficacy, Safety and Tolerability of Oral AK0901 in Children With ADHD

ADHD

China
Merck Sharp & Dohme LLC

Completed

Single-Dose Study of MK-4250 Monotherapy in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-4250-002)

HIV-1 Infection

Germany
BeiGene

Recruiting

Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma

China, Italy, Taiwan, Australia, Spain, Korea, Republic of, France, Thailand, United States, Georgia, Singapore, Canada
BeiGene

Recruiting

Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors

Locally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2

Australia, United States, Spain, France, Italy, Korea, Republic of, Poland
Albireo

Completed

A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384

Primary Biliary Cirrhosis | Alagille Syndrome | Progressive Familial Intrahepatic Cholestasis | Orphan Cholestatic Liver Diseases

Search clinical trials for: A4250 (odevixibat)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations